Compare iShares MSCI Singapore ETF (EWS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Pfizer Inc — how do they compare? iShares MSCI Singapore ETF trades at $33.67, while Pfizer Inc trades at $26.31 (market cap $151.73B). The key difference: Pfizer Inc pays a 6.46% dividend while iShares MSCI Singapore ETF pays none, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| EWS | PFE | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $33.92 | $28.56 |
52-Week Low | $26.71 | $23.60 |
Market Cap | — | $151.73B |
Volume | — | 29,869,932 |
Enterprise Value | — | $203.22B |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $33.68, up 1.54% today and near its 52-week high. Technical indicators show a bullish trend with strong moving average support, though oscillators signal overbought conditions. The ETF benefits from Singapore's economic resilience, AI-driven growth prospects, and a 3.97% dividend yield, with institutional interest rising as Amundi increased holdings by 4.8% in Q2 2026 (SEC filing, 2026-08-05).
Outlook is positive due to Singapore's market reforms and AI infrastructure investments, but risks include concentrated financial sector exposure and regional economic volatility. The bullish technical setup and institutional accumulation support upside potential, though overbought RSI levels warrant caution for near-term entries.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
